Astellas pulls EU filing for telavancin
This article was originally published in Scrip
Astellashas withdrawn the EU marketing authorisation application for its lipoglycopeptide antibiotic telavancin for the treatment of complicated skin and soft tissue infections (CSSTI). The decision came just a few weeks before a US advisory committee is scheduled to consider the product.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.